A randomized, placebo-controlled trial has found that semaglutide, the drug widely known under brand names used for weight loss and diabetes, lowered pulmonary artery wedge pressure during low-intensity exercise in people living with heart failure with preserved ejection fraction and obesity. The study was published in Nature Medicine and presented at the 2026 American Heart Association Scientific Sessions.
Heart failure with preserved ejection fraction is a condition in which the heart's main pumping chamber still contracts normally but fills poorly, so pressure builds up in the lungs and patients feel breathless, especially when active. Obesity is common among these patients, and it is one of the reasons clinicians have been looking for treatments that address more than one problem at once. The trial tested whether semaglutide, compared with a placebo, could improve how the heart and circulation behave under strain.
The primary finding was a reduction in pulmonary artery wedge pressure during low-intensity exercise in the semaglutide group. That measure is a standard indicator of pressure on the left side of the heart, and a lower value suggests the heart is handling filling more easily under activity. According to the report, other hemodynamic parameters also improved, although the reporting material summarized here does not list each of them.
The findings are preliminary in one important sense: they measure how the cardiovascular system responds to a drug, not whether patients feel better or live longer. The notes available for this story do not cover clinical outcomes such as symptoms, hospital admissions or survival, nor do they say how long the benefit lasts outside the exercise conditions tested. The full methods, sample size and length of follow-up are also not described in the material available, so the size and durability of the effect remain open questions for future research.
Credit. Based on reporting by Barry A. Borlaug, Michael D. Jensen, Milton Packer and Yogesh N. V. Reddy for Nature Medicine. Is this your work? Write to us.
33
